The effect of recombinant-human-erythropoietin treatment on tumor radiosensitivity and cancer-associated anemia in the mouse

B JOINER, VK HIRST, SR McKeown, JJA MCALEER, DG HIRST

    Research output: Contribution to journalArticle

    21 Citations (Scopus)

    Abstract

    Recombinant human erythropoietin (rHuEpo) has recently become available for the treatment of chronic anaemia, including that associated with cancer. Carcinoma NT in CBA mice causes a progressive anaemia which can be overcome by daily injections of recombinant human erythropoietin (rHuEpo). This model was used to study the effect of haematocrit on tumour blood flow, growth rate and radiosensitivity, in mice with haematocrits ranging from approximately 38% (control) to 65% (20 U/day rHuEpo). Tumours showed a small but significant slowing in growth rate with higher haematocrit. In vitro studies showed rHuEpo had no direct effect on the growth of NT cells. Tumour-blood flow was measured by two methods in each mouse (Xe-133 clearance and Rubidium-86 uptake). Blood flow showed a tendency to decrease with increasing blood viscosity although this effect was not significant despite the large differences in haematocrit. Although tumour doubling time was prolonged despite the large differences in haematocrit. Although tumour doubling time was prolonged with increasing radiation dose, from 0 (sham irradiated) to 35 Gy, haematocrit was not found to influence the growth delay. This was attributed, to adaptation of the tumour during the relatively slow change in the haematocrit. rHuEpo is being considered for clinical use in anaemic cancer patients. Our data suggest that this treatment will correct haematocrit with no effect on tumour radiosensitivity.
    Original languageEnglish
    Pages (from-to)720-726
    JournalBRITISH JOURNAL OF CANCER
    Volume68
    Issue number4
    Publication statusPublished - Oct 1993

    Fingerprint Dive into the research topics of 'The effect of recombinant-human-erythropoietin treatment on tumor radiosensitivity and cancer-associated anemia in the mouse'. Together they form a unique fingerprint.

    Cite this